Inspire Medical Systems is the dominant commercial platform in the upper airway stimulation (UAS) therapy space for obstructive sleep apnea (OSA). While the company possesses a robust competitive moat, a solid balance sheet with approximately $400 million in liquidity, and zero debt, it is currently navigating severe operational headwinds. These challenges stem from temporary CPT coding transitions, Medicare reimbursement uncertainties (specifically the WISeR program), and a subsequent drop in prior authorization submissions. These administrative disruptions led management to dramatically cut full-year 2026 revenue guidance to $825M–$875M, triggering a sharp selloff. Although compelling clinical data from the 5,000-patient ADHERE registry and the PREDICTOR study presented at SLEEP 2026 reinforce the long-term clinical efficacy and market potential of the Inspire platform, the near-term financial pressure—particularly an expected 9% to 11% year-over-year revenue decline in Q2 2026—warrants a cautious 'Hold' stance until reimbursement and coding clarity stabilize.